## Supporting Information

# One-step immunoassay based on switching peptides for diagnosis of porcine epidemic diarrhea virus (PEDV) using screened $\mathrm{F}_{\mathrm{v}}$-antibodies 

 <br>${ }^{\text {a D Department }}$ of Materials Science and Engineering, Yonsei University, 50 Yonsei-Ro, Seodaemun-Gu, Seoul 03722, Korea<br>${ }^{\text {b }}$ College of Veterinary Medicine, Chungnam National University, Daejeon, 34134, South Korea<br>${ }^{\text {}}$ Korea Institute of Science and Technology (KIST), Seoul, Korea<br>${ }^{\text {d }}$ Institute of Pharmaceutical and Medical Chemistry, Westfälischen Wilhelms-Universität Münster, Muenster, Germany.<br>*To whom correspondence should be addressed<br>*Corresponding author: Jae-Chul Pyun, Tel.: +82 22293 5509; Fax: 822312 5375; Email: jcpyun@yonsei.ac.kr

## Supporting Information



Fig. S1 Expression of RBD antigen from PEDV (strain CV777) S protein for the screening of Fvantibody library. The RBD consisted of 129 amino acid residues ( 21.2 kDa ), which included a part of the $S$ protein (amino acid number from 582 to 781). SDS-PAGE showed the GFP (26.9 kDa ) and His-tag were included in the structure of RBD antigen ( 49 kDa ).

## Supporting Information

A

Randomized CDR3 region (33 bp)


Randomized CDR3 region (33 bp)


Site-directed mutagenesis

$F_{V}$-antibody library plasmid with randomized CDR3
B




Fig. S2 An autodisplayed $\mathrm{F}_{\mathrm{V}}$-library with a randomized CDR3 region was used to screen for $\mathrm{F}_{\mathrm{V}^{-}}$ antibodies against PEDV $S$ protein. (A) Preparation of the $\mathrm{F}_{\mathrm{V}}$-library with a randomized CDR3 region in the $\mathrm{V}_{\mathrm{H}}$ using site-directed mutagenesis. (B) Expression of the $\mathrm{F}_{\mathrm{V}}$-library on the outer membrane of $E$. coli using an autodisplay vector (SDS-PAGE of the autodisplayed $\mathrm{F}_{\mathrm{V}}$-variant, control strain with CDR1 and CDR2, and intact E. coli).

## Supporting Information



Fig. S3 Specificity test of Fv-antibodies (Anti-RBD-1, Anti-RBD-2, Anti-RBD-3, and Anti-RBD-4) using the positive sample (PEDV) and negative control samples (HCoV-229E, SARS-CoV-1, and SARS-CoV-2) to Fv-antibodies.

## Supporting Information



Fig. S4 Quantitative analysis of the RNA from PEDV in supernatant media of Vero cell was extracted using Patho Gene-spin ${ }^{\text {TM }}$ DNA/RNA extraction kit from iNtRON Biotechnology (Gyeonggi-do, Korea). The amount of RNA from each diluted PEDV samples were analyzed using PEDV PCR reaction kit from iNtRON Biotechnology (Gyeonggi-do, Korea). The PCR reaction was performed according to the manufacturer's instructions. After PCR reaction. the band intensity was calculated using software (ImageJ).

## Supporting Information



Fig. S5 Analysis of interaction between screened $F_{V}$-antibodies (Anti-RBD-1, Anti-RBD-2, Anti-RBD-3, Anti-RBD-4) and RBD antigen from PEDV S protein (Uniprot ID: Q91AV1) using molecular docking software.

Table S1. Primer sequences of randomized CDR3 region of the $F_{v}$-antibody library. Randomized forward primer ( 75 bases) and corresponding reverse primer ( 22 bases) and composition of nucleotides at each position were listed in the table.

| Primer type | Oligonucleotide sequence |
| :---: | :---: |
| Randomized forward primer <br> (75 bases) | 5’-GTCTATTATTGCGCTCGT ${ }^{1}$ KRYVNN ${ }^{7}$ VNNVNN ${ }^{13}$ VNNVNN ${ }^{19}$ VNNVNN ${ }^{25}$ VNNGAT ${ }^{31}$ KWYTGGGGTCAAGGTACTACGGTTACG-3' |
| Corresponding reverse primer <br> (22 bases) | 3'-CCCAGTTCCATGATGCCAATGC-5' |
| Composition of nucleotides at each position | $\mathbf{N}=\mathrm{A}, \mathrm{C}, \mathrm{G}, \mathrm{T} / \mathbf{R}=\mathrm{A}, \mathrm{G} / \mathbf{K}=\mathrm{G}, \mathrm{T} / \mathbf{Y}=\mathrm{C}, \mathrm{T} / \mathbf{W}=\mathrm{A}, \mathrm{T} / \mathbf{V}=\mathrm{A}, \mathrm{C}, \mathrm{G}$ |

## Supporting Information

Table S2. Amino acid and corresponding oligonucleotide sequences of $\mathrm{F}_{\mathrm{V}}$-antibody. The CDR3 sequence was randomized for the preparation of $\mathrm{F}_{\mathrm{V}}$-antibody library from the template using site-directed mutagenesis.

| Region | Amino acid ( $\mathrm{N} \rightarrow$ C-term) | Oligonucleotide sequence ( $5^{\prime} \rightarrow 3^{\prime}$ ) |
| :---: | :---: | :---: |
| Frame-1 | EVQLVESAAEVRRPGASVKITCKASGYSFS | GAA GTG CAG CTC GTG GAA AGC GCT GCC GAA GTT CGG CGT CCT GGG GCT AGC GTG AAG ATC ACC TGC AAA GCG TCC GGC TAT TCA TTC AGC |
| CDR1 | TYGIQ | ACC TAT GGG ATT CAG |
| Frame-2 | WMRQAPGQRPEWLG | TGG ATG CGC CAA GCG CCA GGC CAG CGT CCG GAA TGG CTT GGG |
| CDR2 | WIHAGTGGTKYSRKFQG | TGG ATA CAT GCA GGC ACA GGT GGG ACT AAG TAC TCG CGC AAA TTT CAG GGT |
| Frame-3 | RITITRDTSANTVYLDLNSLTSEDTAVYYCAR | CGC ATT ACT ATC ACC CGT GAT ACC AGC GCG AAT ACC GTC TAT CTG GAT CTG <br> AAC TCT CTG ACA TCG GAG GAT ACG GCC GTC TAT TAT TGC GCT CGT |
| CDR3 <br> (Template) | DKVTVWACQDN | GAC AAA GTT ACA GTC TGG GCT TGT CAG GAT AAT |
| Frame-4 | WGQGTTVTVSS | TGG GGT CAA GGT ACT ACG GTT ACG GTC AGC AGT |

## Supporting Information

Table S3. Analytic parameters of L1-switching peptide. The peptide was synthesized from Peptron Co. (Daejeon, Korea) using solid-phase Fmoc chemistry under consecutive flow conditions. The synthesized peptides were purified using reverse-phase HPLC (High-Performance Liquid Chromatography) and lyophilized.

| Switching peptide | Amino acid sequence | Molecular weight (g/mol) | Purity |
| :--- | :--- | :--- | :--- |
| L1-peptide | TYLEW $^{5}$ YPQKP $^{10}$ GQSPK $^{15}$ LLIYK $^{20}$ | 2,452 | $90 \%$ |

